Prot #MGL‐3196‐19: A Randomized Double‐blind Placebo‐controlled Phase 3 Study to Evaluate the Effect of Resmetirom on Liver‐related Outcomes in Patients with Well‐compensated (Child‐Pugh A) Non‐alcoholic Steatohepatitis (NASH) Cirrhosis (MAESTRO‐NASH OUTC

Project: Research project

Project Details

Effective start/end date5/23/235/23/26


  • INC Research, LLC (Prot #MGL-3196-19 AMD 1 // Prot #MGL-3196-19 AMD 1)
  • Synta Pharmaceuticals Corp. (Prot #MGL-3196-19 AMD 1 // Prot #MGL-3196-19 AMD 1)